Jorge Cortes, MD, Augusta University, Augusta, GA, gives an update on a Phase I/II study evaluating the safety and efficacy of vodobatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who have received three or more prior tyrosine kinase inhibitors (TKIs) including ponatinib (NCT02629692). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.